Actively Recruiting
Randomized, Double-Blind Study of Atumelnant Versus Placebo in Adults With Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency
Led by Crinetics Pharmaceuticals Inc. · Updated on 2026-10-16
150
Participants Needed
75
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy, safety, pharmacokinetics PK, and pharmacodynamics PD of atumelnant in adults with classic congenital adrenal hyperplasia CAH caused by 21-hydroxylase deficiency 21-OHD. This Phase 3, global, multicenter, randomized, double-blind, placebo-controlled study involves adults aged 18 to under 75 years who have been on a stable glucocorticoid GC regimen for at least 2 months. The study aims to understand how atumelnant works and how safe it is for this population. Participants will be randomly assigned in a 21 ratio to receive either atumelnant tablets or a matching placebo once daily for 32 weeks. The atumelnant dose starts at 80 mg daily with an option to increase to 120 mg daily at Week 20 if needed. Before treatment, participants undergo a 3- to 6-week screening period to confirm eligibility. Approximately 150 participants may take part worldwide. During the study, participants will have regular assessments including hormone level measurements such as morning post-GC androstenedione A4 to evaluate response. Researchers will monitor glucocorticoid doses, safety, and other health indicators. The main outcome is the proportion of participants achieving morning post-GC A4 levels at or below the upper limit of normal while on physiologic GC replacement at Week 32. The total participation time includes screening plus 32 weeks of treatment and evaluations.
CONDITIONS
Brief Title
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
Research Team
C
Crinetics Clinical Trials
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here